Trulicity History & Development: How Dulaglutide Was Discovered, Engineered, and Approved

The direct answer

Dulaglutide is not a new molecular idea. It is an engineering solution to a problem that GLP-1 research had already identified by the early 2000s: native GLP-1 and early analogs like exenatide clear from the body too fast for convenient dosing. Eli Lilly's answer was to fuse a modified GLP-1 peptide to a human IgG4 antibody fragment, which slows breakdown and clearance enough to allow once-weekly injection. That single design decision, made years before weight loss became the center of GLP-1 drug competition, explains both what dulaglutide is good at (glycemic control, cardiovascular risk reduction, tolerability, dosing simplicity) and what it is not built to maximize (weight loss, relative to newer agents engineered around different tradeoffs).

The cardiovascular benefit shown in the REWIND trial is real and FDA-recognized in the drug's label, but it applies specifically to adults with type 2 diabetes, not to the general population, and it has not been shown to extend to children or to people without diabetes. That boundary matters more than any single efficacy number in this article.

Why researchers were chasing GLP-1 drugs at all

The broader scientific story starts before Lilly's involvement. In the early 1990s, researcher John Eng characterized exendin-4, a peptide isolated from the venom of the Gila monster (Heloderma suspectum), which shares partial sequence similarity with human glucagon-like peptide-1 (GLP-1) but resists rapid breakdown by the enzyme dipeptidyl peptidase-4 (DPP-4). That resistance to degradation is what made a GLP-1-based drug class commercially feasible, since native human GLP-1 has a plasma half-life of only a few minutes and would otherwise require continuous infusion to have a sustained effect.

Exenatide (Byetta), approved in 2005, was the first GLP-1 receptor agonist on the market, but it required twice-daily injections because its half-life was still short. Liraglutide (Victoza), approved by the FDA in 2010, extended dosing to once daily using fatty-acid acylation, a chemical modification that promotes binding to albumin in the blood and slows clearance. The next open question in the field was whether a GLP-1 drug could be engineered for once-weekly dosing without sacrificing tolerability or requiring reconstitution before injection.

How Lilly's Fc-fusion design changed the half-life problem

Lilly took a different engineering route than the fatty-acid approach used for liraglutide and, later, semaglutide. Instead of attaching a fatty acid, Lilly's researchers fused a modified GLP-1 peptide to the Fc region of human immunoglobulin G4 (IgG4), the same structural region that gives antibodies their long circulating half-life.

IgG4 antibodies are recycled through the neonatal Fc receptor (FcRn) pathway inside cells rather than being routed for lysosomal degradation. When dulaglutide binds FcRn inside endosomes, it is trafficked back to the cell surface and released into circulation rather than broken down. Combined with the molecule's larger size as a roughly 60-kilodalton homodimer, which reduces how quickly the kidneys filter it out, this recycling mechanism is the reason dulaglutide can be dosed once weekly instead of daily.

To make the fusion work, the underlying GLP-1 peptide itself needed modification. Published pharmacology work describes two amino acid substitutions in the peptide portion: one that blocks the site where DPP-4 would normally cleave the molecule, and a second intended to reduce aggregation of the peptide once it is linked to the Fc fragment. A synthetic linker then attaches two copies of this modified peptide to the antibody-derived scaffold, so each dulaglutide molecule presents two GLP-1 receptor-binding sites. The exact residue numbering and structural detail described in some public summaries of this chemistry should be verified against Lilly's original structural characterization papers before being cited as precise fact; the general design logic (peptide modification plus Fc fusion) is well established, but specific figures require primary-source confirmation.

Using a human antibody fragment rather than a foreign protein scaffold was also an immunogenicity-reduction strategy. Trial programs reported low rates of detectable anti-drug antibodies and no clear pattern of hypersensitivity linked to those antibodies, though exact percentages from the individual AWARD trials should be checked against the original publications rather than treated as fixed figures here.

What the AWARD phase III program actually established

Lilly's phase III program for dulaglutide, known as AWARD, ran across multiple trials comparing dulaglutide to placebo, metformin, exenatide twice daily, sitagliptin, insulin glargine, insulin lispro, and liraglutide, in various combinations, enrolling several thousand participants with type 2 diabetes in total.

Across this program, the consistent finding reported in the literature is that dulaglutide, at its standard 1.5 mg once-weekly dose, produced HbA1c reductions that matched or exceeded the comparator drugs it was tested against, including a head-to-head trial against once-daily liraglutide in which dulaglutide met a pre-specified non-inferiority margin. Weight loss across these trials was modest, generally in the low single-digit kilogram range, smaller than what was later reported for liraglutide at its higher weight-management dose and substantially smaller than what more recent agents (semaglutide, tirzepatide) later demonstrated.

Specific HbA1c reductions, confidence intervals, and p-values from individual AWARD trials are not provided in this summary due to inability to independently confirm the available literature sources against original trial reports. Clinicians who need precise efficacy data from a particular AWARD study should consult the published trial results or FDA review materials rather than relying on secondary sources like this article.

FDA approval, September 2014

The FDA approved dulaglutide under the brand name Trulicity in September 2014, for adults with type 2 diabetes as an adjunct to diet and exercise. The initial approval covered the 0.75 mg and 1.5 mg once-weekly doses, delivered by a single-dose autoinjector pen that does not require reconstitution or a separate needle-attachment step. That device design, rather than any single trial result, is widely credited with dulaglutide's relatively strong real-world adherence compared with drugs requiring more injection steps, though adherence comparisons across the class should be interpreted cautiously since they depend heavily on study design and population.

At the time dulaglutide was approved, FDA guidance already required manufacturers of new type 2 diabetes drugs to demonstrate that the drug did not carry unacceptable cardiovascular risk, which is why a dedicated cardiovascular outcomes trial (REWIND) was already underway or planned at approval.

What REWIND showed, and what it did not show

REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) was a large, long cardiovascular outcomes trial of dulaglutide in adults with type 2 diabetes, published in The Lancet in 2019. Its design differed from earlier GLP-1 cardiovascular trials such as LEADER (liraglutide) and SUSTAIN-6 (semaglutide) in an important way: REWIND enrolled a broader population, with roughly a third of participants having established cardiovascular disease at baseline and the remainder having cardiovascular risk factors without confirmed disease. Median follow-up was longer than most comparable trials, at roughly five years.

The trial's primary composite outcome, first occurrence of nonfatal heart attack, nonfatal stroke, or cardiovascular death, was reduced with dulaglutide compared with placebo, and the result was statistically significant, though modest in absolute terms. The reduction in nonfatal stroke appears to have been the larger driver of the composite result, while cardiovascular death alone was not significantly reduced. A pre-specified kidney-related composite outcome (substantial decline in kidney function, macroalbuminuria, or need for renal replacement therapy) was also reduced. An exploratory cognition sub-study reported a smaller measured decline in a cognitive screening score among dulaglutide-treated participants, but this finding is exploratory and requires confirmation in a dedicated trial before it should influence treatment decisions.

Following REWIND, the FDA updated dulaglutide's label in 2020 to include a cardiovascular risk-reduction indication for adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Major diabetes guideline bodies, including the American Diabetes Association's Standards of Care and the Endocrine Society's clinical practice guideline on type 2 diabetes, now list GLP-1 receptor agonists with demonstrated cardiovascular benefit, dulaglutide among them, as preferred options for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, independent of baseline HbA1c. Readers who want the exact guideline wording should consult the ADA Standards of Care and the Endocrine Society guideline page directly rather than a paraphrased quotation, since the exact current text should be checked against the live guideline rather than reproduced from a secondary source.

What this establishes, and its boundary: dulaglutide has FDA-labeled evidence of cardiovascular risk reduction specifically in adults with type 2 diabetes who have cardiovascular disease or elevated cardiovascular risk, based on REWIND. It does not establish a cardiovascular benefit in people without type 2 diabetes, in children, or as a weight-loss-first strategy. The mechanism behind the cardiovascular signal, whether it is fully explained by glucose lowering or reflects a separate vascular or anti-inflammatory effect, remains an area of ongoing research rather than settled fact.

Dose expansion and pediatric approval

In January 2020, alongside the cardiovascular label update, the FDA approved two higher once-weekly doses of dulaglutide, 3.0 mg and 4.5 mg, intended for patients who needed more glycemic control without adding a second drug. Trial data supporting these doses reported greater HbA1c reduction and modestly greater weight loss at the higher doses compared with 1.5 mg, though even at 4.5 mg, dulaglutide's weight-loss effect remains smaller than what has been reported for semaglutide 2.4 mg or tirzepatide in their respective obesity trials.

In 2023, the FDA extended dulaglutide's approval to adolescents aged 10 and older with type 2 diabetes, based on a pediatric trial showing meaningful HbA1c reduction compared with placebo over roughly six months. This pediatric approval rests on glycemic control, not on cardiovascular outcomes; REWIND enrolled adults only, so the cardiovascular benefit shown in adults should not be assumed to apply to adolescents.

How dulaglutide works, in plain terms

The GLP-1 receptor is a cell-surface receptor found on pancreatic beta cells (which make insulin), pancreatic alpha cells (which make glucagon), cells in the heart and kidney, and nerve pathways connecting the gut to the brain. When dulaglutide binds this receptor, it triggers a signaling cascade that increases insulin release, but only when blood glucose is already elevated, which is why GLP-1 receptor agonists carry a relatively low intrinsic hypoglycemia risk compared with drugs like sulfonylureas.

Dulaglutide also suppresses glucagon release after meals, which reduces how much glucose the liver releases into the bloodstream, and it slows gastric emptying, which flattens the post-meal glucose spike but also explains the nausea, vomiting, and abdominal discomfort that are the most common side effects, especially in the first several weeks of treatment. Effects on brain appetite centers contribute to modest weight loss, though this effect is smaller with dulaglutide than with drugs engineered specifically around appetite suppression at higher relative potency.

Where dulaglutide fits now, next to newer GLP-1 drugs

The competitive landscape for GLP-1-based drugs changed substantially after semaglutide's approval for chronic weight management (Wegovy) and tirzepatide's approvals for type 2 diabetes (Mounjaro) and obesity (Zepbound). Both newer drugs have demonstrated larger average weight loss than dulaglutide in their respective trial programs. Dulaglutide's comparative advantage is not weight loss; it is a longer track record of cardiovascular outcomes data in a broad type 2 diabetes population, a well-characterized tolerability profile built on roughly a decade of use, and a delivery device that does not require the patient to handle a visible needle.

For a patient whose main treatment goal is cardiovascular risk reduction or glycemic control with a simple weekly injection, and for whom substantial weight loss is not the primary objective, dulaglutide remains a reasonable, evidence-supported option. For a patient whose primary goal is weight loss, the trial evidence available for semaglutide and tirzepatide shows larger effect sizes, and that difference should be discussed directly with a prescriber rather than assumed.

Decision framework: what dulaglutide's engineering history should and shouldn't decide for you

This framework connects each major design choice in dulaglutide's development to what it actually bought clinically, what it did not buy, and the practical question a patient or clinician should ask next.

None of these rows are a substitute for an individualized conversation about dosing, contraindications, or alternatives with a prescriber. They are meant to keep the historical facts in this article from being overgeneralized into a treatment decision they were never designed to support.

Evidence boundary: what is established, what is plausible, what is not

Established: dulaglutide is an FDA-approved GLP-1 receptor agonist, first cleared for type 2 diabetes in 2014, built as an Fc-fusion protein that enables once-weekly dosing. A cardiovascular risk-reduction indication was added in 2020 based on the REWIND trial, in adults with type 2 diabetes who have cardiovascular disease or elevated risk. Pediatric approval (2023) is based on glycemic, not cardiovascular, evidence.

Plausible but not fully settled: whether dulaglutide's cardiovascular benefit reflects a direct vascular or anti-inflammatory effect of GLP-1 receptor activation, separate from its effect on blood glucose, or is substantially explained by glucose lowering itself. The cognitive-outcome signal reported in REWIND's sub-study is exploratory and unconfirmed.

Not established: that dulaglutide offers a cardiovascular or glycemic benefit outside adults with type 2 diabetes; that it is an effective or approved weight-loss treatment on its own; or that its long real-world track record makes it clinically superior to newer, more potent GLP-1-based drugs for patients whose goal is significant weight reduction.

If a specific number from a trial matters to a treatment decision, whether an HbA1c delta, a hazard ratio, or a confidence interval, it should be pulled from the primary trial publication or the FDA's own review documents rather than taken from any secondary summary, including this one.

A note on sources: several precise trial figures that appeared in earlier drafts of this history (exact HbA1c deltas by trial, specific hazard ratios, exact antibody incidence percentages) have been removed or softened here because the specific literature identifiers available could not be independently verified against the underlying publications for this draft. This is a gap to close during medical and editorial review, ideally by pulling the AWARD trial papers, the REWIND primary publication, and the FDA's approval and clinical pharmacology review documents directly, rather than relying on secondary citation chains.